NASDAQ:ACER - Acer Therapeutics Stock Price, Forecast & News

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

Acer Therapeutics Inc (NASDAQ:ACER) released its earnings results on Wednesday, November, 13th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.57) by $0.05. View Acer Therapeutics' Earnings History.

Acer Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Acer Therapeutics.

5 brokers have issued 12-month target prices for Acer Therapeutics' stock. Their forecasts range from $9.00 to $48.00. On average, they expect Acer Therapeutics' share price to reach $22.33 in the next twelve months. This suggests a possible upside of 332.8% from the stock's current price. View Analyst Price Targets for Acer Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Acer Therapeutics.

News coverage about ACER stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Acer Therapeutics earned a news impact score of -3.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Acer Therapeutics.

Acer Therapeutics saw a drop in short interest in the month of January. As of January 15th, there was short interest totalling 442,900 shares, a drop of 8.8% from the December 31st total of 485,900 shares. Based on an average trading volume of 50,200 shares, the short-interest ratio is currently 8.8 days. Currently, 9.1% of the shares of the stock are short sold. View Acer Therapeutics' Current Options Chain.

Some companies that are related to Acer Therapeutics include Abeona Therapeutics (ABEO), Theratechnologies (THTX), Affimed (AFMD), Arbutus Biopharma (ABUS), Athersys (ATHX), Nature's Sunshine Products (NATR), Five Prime Therapeutics (FPRX), TAIWAN LIPOSOME/S (TLC), Chiasma (CHMA), Scpharmaceuticals (SCPH), Fortress Biotech (FBIO), Evelo Biosciences (EVLO), Kezar Life Sciences (KZR), Akorn (AKRX) and Spero Therapeutics (SPRO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Sarepta Therapeutics (SRPT), NVIDIA (NVDA), Synergy Pharmaceuticals (SGYP), NovaBay Pharmaceuticals (NBY), Advanced Micro Devices (AMD), Amarin (AMRN), Novavax (NVAX), Arena Pharmaceuticals (ARNA), Anavex Life Sciences (AVXL) and Exelixis (EXEL).

Acer Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (1.10%), Barclays PLC (0.97%), J. Goldman & Co LP (0.73%), Goldman Sachs Group Inc. (0.51%), Bank of Montreal Can (0.14%) and CWS Financial Advisors LLC (0.10%). Company insiders that own Acer Therapeutics stock include Life Science Ventures Vii Tvm and Steve Aselage. View Institutional Ownership Trends for Acer Therapeutics.

ACER stock was sold by a variety of institutional investors in the last quarter, including J. Goldman & Co LP, Goldman Sachs Group Inc., State Street Corp and Bank of Montreal Can. View Insider Buying and Selling for Acer Therapeutics.

ACER stock was acquired by a variety of institutional investors in the last quarter, including CWS Financial Advisors LLC, UBS Group AG and Barclays PLC. Company insiders that have bought Acer Therapeutics stock in the last two years include Life Science Ventures Vii Tvm and Steve Aselage. View Insider Buying and Selling for Acer Therapeutics.

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ACER stock can currently be purchased for approximately $5.16.

Acer Therapeutics has a market capitalization of $52.12 million. The biopharmaceutical company earns $-21,280,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Acer Therapeutics employs 23 workers across the globe.View Additional Information About Acer Therapeutics.

The official website for Acer Therapeutics is http://www.acertx.com/.

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]